Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (361-370 of 411) with videos related to

Pageof 42
Sort By:
Frontiers in Cell and Developmental Biology|November 19, 2019
Studying Brugada Syndrome With an SCN1B Variants in Human-Induced Pluripotent Stem Cell-Derived CardiomyocytesIbrahim El-Battrawy, Jonas Müller, Zhihan Zhao, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Nature Communications|June 1, 2017
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesionsAntje Sucker, Fang Zhao, Natalia Pieper, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaDirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaIvelina Spassova, Selma Ugurel, Linda Kubat, et al.
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
Oncogene|July 12, 2018
RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomasManfred Kunz, Henry Löffler-Wirth, Michael Dannemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Cancers|June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg StudyHenner Stege, Maximilian Haist, Michael Schultheis, et al.
Pageof 42

Showing results (361-370 of 411) with videos related to

Sort By:
Pageof 42
Frontiers in Cell and Developmental Biology|November 19, 2019
Studying Brugada Syndrome With an SCN1B Variants in Human-Induced Pluripotent Stem Cell-Derived CardiomyocytesIbrahim El-Battrawy, Jonas Müller, Zhihan Zhao, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Nature Communications|June 1, 2017
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesionsAntje Sucker, Fang Zhao, Natalia Pieper, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaDirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaIvelina Spassova, Selma Ugurel, Linda Kubat, et al.
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
Oncogene|July 12, 2018
RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomasManfred Kunz, Henry Löffler-Wirth, Michael Dannemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Cancers|June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg StudyHenner Stege, Maximilian Haist, Michael Schultheis, et al.
Pageof 42